血液系统恶性肿瘤脾切除术疗效:回顾性队列研究
该回顾性队列研究纳入2009至2024年在一家NCI指定综合癌症中心接受脾切除术的79例血液系统疾病患者,按适应证分为淋系、髓系等组。结果显示30天并发症率为49%(≥3级22%),桥接移植成功率达91.7%,而实现输血脱离的成功率在细胞减少患者中较低(淋系38.5%、移植后髓系40%、ITP 40%)。
要点
- 脾切除术30天总并发症率为49%,其中≥3级并发症占22%。
- 桥接移植的脾切除术成功率为91.7%,是有效性最高的适应证。
- 实现输血脱离的成功率在淋系、移植后髓系和ITP患者中均为38.5%–40%。
核心结论
- 当代血液系统恶性肿瘤患者中,脾切除术的成功率因适应证而异,但总体可产生良好结局,包括改善输血依赖和成功桥接至确定性治疗。
研究设计与样本
- 回顾性队列研究,纳入2009至2024年在一家NCI指定综合癌症中心连续接受脾切除术的79例血液系统疾病患者。
- 患者按适应证分为淋系(37例)、髓系(33例)、免疫性血小板减少性紫癜(ITP,5例)和其他(4例)。
- 主要结局为术后30天并发症率,次要结局为基于适应证的脾切除术成功率。
主要发现
- 适应证包括桥接移植(35.4%)、输血依赖(24.0%)、症状性血细胞减少(22.8%)和脾脏恶性肿瘤(17.7%)。
- 30天并发症率总体为49%,≥3级并发症为22%。
- 髓系患者发生任何并发症的比例为65.5%,淋系为46.4%(P=0.482)。
- 桥接移植成功率为91.7%;实现输血脱离的成功率在淋系为38.5%、移植后髓系为40%、ITP为40%。
临床怎么用
- 脾切除术用于血液系统恶性肿瘤时,应依据适应证评估预期成功率,桥接移植成功率较高,而实现输血脱离的成功率相对较低。
- 术后30天并发症率较高(49%),需加强围术期管理,尤其关注≥3级并发症(22%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to define the evolving indications for splenectomy and benchmark clinical outcomes in patients with hematologic malignancies. BACKGROUND: With the advent of new therapies for hematologic malignancies, the diagnostic and therapeutic indications for splenectomy have changed. However, the effectiveness of splenectomy and its postoperative complications are not well understood. METHODS: This retrospective study included consecutive patients with hematologic disorders who underwent splenectomy at an NCI-designated comprehensive cancer center between 2009 and 2024. Patients were grouped by indication as lymphoid or myeloid; patients with benign conditions constituted a small descriptive subgroup. The primary outcome was the postoperative complication rate (30 d). The secondary outcome was splenectomy success based on indications. RESULTS: A total of 79 patients were included: 37 lymphoid, 33 myeloid, 5 immune thrombocytopenic purpura (ITP), and 4 others. Indications included bridge-to-transplant (35.4%), transfusion dependence (24.0%), symptomatic cytopenia (22.8%), and splenic malignancy (17.7%). The 30-day complication rate was 49% overall (22% grade 3 or higher). While myeloid patients had a higher proportion of patients experiencing any complication compared to lymphoid patients (65.5% vs 46.4%) (P=0.482). Success rates were 91.7% for bridge-to-transplant but lower for achieving transfusion independence in cytopenia (38.5% lymphoid patients, 40% post-transplant myeloid patients, and 40% ITP patients). CONCLUSIONS: Our results benchmark postoperative outcomes of splenectomy in a contemporary cohort with hematological malignancies. The success of splenectomy varies according to indication. Appropriate splenectomy produces favorable outcomes across a broad range of hematologic malignancies, including improved transfusion independence and successful bridging to definitive therapies.
引用
- Mohammed H, Waheed MT, Trisal V, et al. Efficacy of Splenectomy for Hematologic Malignancies: A Retrospective Cohort Study. Ann Surg. 2026. PMID: 42440087. doi:10.1097/SLA.0000000000007139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。